Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutanenous Bioresorbable CUV1647 Implants in Patients With Erythropoietic Protoporphyria (EPP) (Report)
We have been working with MT2 peptides for over 10 years, building long-term relationships with thousands of returning customers across Australia
Tissue Inhibitors of Metalloproteinases (TIMPs) TIMPs increase across all concentrations tested (0.01-100 nM)
It is provided solely for laboratory research purposes and must not be used for diagnostic or therapeutic purposes, in food, cosmetics, or any medical applications
US$ 29.85
US$ 24.82
US$ 25.40
